AU2002358535B2 - Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition - Google Patents
Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition Download PDFInfo
- Publication number
- AU2002358535B2 AU2002358535B2 AU2002358535A AU2002358535A AU2002358535B2 AU 2002358535 B2 AU2002358535 B2 AU 2002358535B2 AU 2002358535 A AU2002358535 A AU 2002358535A AU 2002358535 A AU2002358535 A AU 2002358535A AU 2002358535 B2 AU2002358535 B2 AU 2002358535B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- hydrogen atom
- formula
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000005764 inhibitory process Effects 0.000 title abstract description 10
- 102000029816 Collagenase Human genes 0.000 title abstract description 7
- 108060005980 Collagenase Proteins 0.000 title abstract description 7
- QZMMMOWLQLKASC-UHFFFAOYSA-N pyrimidine-4,6-dicarboxamide Chemical class NC(=O)C1=CC(C(N)=O)=NC=N1 QZMMMOWLQLKASC-UHFFFAOYSA-N 0.000 title abstract description 7
- OOXOXZVOZIURRD-UHFFFAOYSA-N pyridine-2,4-dicarboxamide Chemical class NC(=O)C1=CC=NC(C(N)=O)=C1 OOXOXZVOZIURRD-UHFFFAOYSA-N 0.000 title abstract description 6
- 229960002424 collagenase Drugs 0.000 title abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 91
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 82
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 55
- 150000002367 halogens Chemical class 0.000 claims description 55
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- -1 methoxy, methyl Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 18
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 17
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 239000011737 fluorine Substances 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 239000011593 sulfur Substances 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 9
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 150000008064 anhydrides Chemical class 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 208000036487 Arthropathies Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058112 Chondrolysis Diseases 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000004097 bone metabolism Effects 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000003137 locomotive effect Effects 0.000 claims description 2
- 230000005499 meniscus Effects 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 210000004417 patella Anatomy 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 12
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 102100027995 Collagenase 3 Human genes 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- XIEOKRXVAACBHI-UHFFFAOYSA-N pyrimidine-4,6-dicarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=NC=N1 XIEOKRXVAACBHI-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 108020001778 catalytic domains Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108091007196 stromelysin Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 230000036570 collagen biosynthesis Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- PHLZUDXEBCQHKM-UHFFFAOYSA-N (3,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(F)=C1 PHLZUDXEBCQHKM-UHFFFAOYSA-N 0.000 description 1
- LQAUXDMGRBWDIU-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(Cl)=C1 LQAUXDMGRBWDIU-UHFFFAOYSA-N 0.000 description 1
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- RAFAYWADRVMWFA-UHFFFAOYSA-N 4,6-dimethyl-1h-pyrimidine-2-thione Chemical compound CC1=CC(C)=NC(S)=N1 RAFAYWADRVMWFA-UHFFFAOYSA-N 0.000 description 1
- LSBIUXKNVUBKRI-UHFFFAOYSA-N 4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC=N1 LSBIUXKNVUBKRI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- ZJZLVWUBAFCQSI-UHFFFAOYSA-N 4-n,6-n-bis[(3-chloro-4-fluorophenyl)methyl]pyrimidine-4,6-dicarboxamide Chemical compound C1=C(Cl)C(F)=CC=C1CNC(=O)C1=CC(C(=O)NCC=2C=C(Cl)C(F)=CC=2)=NC=N1 ZJZLVWUBAFCQSI-UHFFFAOYSA-N 0.000 description 1
- JKTYGPATCNUWKN-UHFFFAOYSA-N 4-nitrobenzyl alcohol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1 JKTYGPATCNUWKN-UHFFFAOYSA-N 0.000 description 1
- IQYHIELCNXQLGM-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1CNC2 IQYHIELCNXQLGM-UHFFFAOYSA-N 0.000 description 1
- BMAGKXIIOLHBNO-UHFFFAOYSA-N 6-(dibenzylcarbamoyl)pyrimidine-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(C(=O)N(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=N1 BMAGKXIIOLHBNO-UHFFFAOYSA-N 0.000 description 1
- LMHSNOZVBRPSDC-UHFFFAOYSA-N 6-(diethylcarbamoyl)pyrimidine-4-carboxylic acid Chemical compound CCN(CC)C(=O)C1=CC(C(O)=O)=NC=N1 LMHSNOZVBRPSDC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- BWEQSGJKNHMSPA-UHFFFAOYSA-N N.ON Chemical compound N.ON BWEQSGJKNHMSPA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940076134 benzene Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 101150114085 soc-2 gene Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229950011008 tetrachloroethylene Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229960002415 trichloroethylene Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention concerns pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides of formula (I) for selective collagenase (MPP 13) inhibition. Said pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides can therefore be used for treating degenerative joint diseases.
Description
WO 03/049738 PCT/EP02/13240 Description Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition The invention relates to the use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic diamides for selectively inhibiting collagenase (MMP 13).
The pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides can therefore be employed for treating degenerative diseases of the joints.
It is known that pyrimidine-4,6-dicarboxylic acid diamides and 2,4-substituted pyridine-N-oxides inhibit the enzymes proline hydroxylase and lysine hydroxylase and thereby bring about an inhibition of collagen biosynthesis by influencing the collagen-specific hydroxylation reaction (EP 0418797; EP 0463592). This inhibition of collagen biosynthesis results in the formation of a nonfunctional, underhydroxylated collagen molecule which can only be released by the cells into the extracellular space in small quantity. In addition, the underhydroxylated collagen cannot be incorporated into the collagen matrix and is very easily broken down proteolytically. As a consequence of these effects, the overall quantity of extracellularly deposited collagen decreases.
In diseases such as osteoarthritis and rheumatism, the joint is destroyed, due, in particular, to the proteolytic degradation of collagen by collagenases. Collagenases belong to the metalloproteinase (MP) or matrix metalloproteinase (MMP) superfamily. MMPs cleave collagen, laminin, proteoglycans, elastin or gelatin under physiological conditions and therefore play an important role in bone and connective tissue. A large number of different inhibitors of the MMPs or the collagenases are known (EP 0 606 046; W094/28889). The known inhibitors of the MMPs frequently suffer from the disadvantage that they lack the specificity of inhibiting only one class of the MMPs. As a result, most MMP inhibitors inhibit several MMPs at the same time because the catalytic domains of the MMPs exhibit similar structures. As a consequence, the inhibitors act, in an undesirable manner, on many enzymes, including those which have a vital function (Massova et al., The FASEB Journal (1998)12, 1075-1095).
In an endeavor to find active compounds for treating connective tissue diseases, it has now been found that the compounds which are employed in accordance with the invention are powerful inhibitors of matrix metalloproteinase 13 whereas they are essentially inactive in the case of MMPs 3 and 8.
The invention therefore relates to the use of compounds of the formula I 0 o
RI
S
N
A
N
H H R2 R3 3R3 R3 and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of formula I, for producing a pharmaceutical for the prophylaxis and therapy of diseases whose course involves an increased activity of matrix metalloproteinase 13, where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. halogen, 3. -(C 1 -C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 4. -O-(C 1
-C
4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, in which R4 is hydrogen atom or -(C1-C4)-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. 1
-C
4 )-alkyl or 4. -S0 2
-(C
1
-C
4 )-alkyl, 8. -OH, 9. -S-(C 1
-C
4 )-alkyl, -S(O)-(C1-C4)-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C1-C4)-alkyl, -OH or -NH 2 R2 is 1. hydrogen atom, 2. halogen, 3. -O-(C 1
-C
4 )-alkyl, 4. -(C 1 -C4)-alkyl, in which R4 is hydrogen atom or -(C 1 -C4)-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(Cl-C 4 )-alkyl, 3. 1 -C4)-alkyl or 4. -SO 2
-(C
1
-C
4 )-alkyl, 8. -OH, 9. -S-(C 1 -C4)-alkyl, 1 -C4)-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C 1
-C
4 )-alkyl, -OH or -NH 2 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 11.
The invention furthermore relates to the use of compounds of the formula I where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. halogen, 3. -(C 1
-C
4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 4. -O-(C 1
-C
4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 1. hydrogen atom, 2. halogen, 3. -O-(C 1
-C
4 )-alkyl, or 4. -(C 1
-C
4 )-alkyl, or R2 is R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 4.
The invention furthermore relates to the use of compounds of the formula I where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, 6. methyl, 7. -C(O)-OH, 8. -C(O)-O-CH 3 9. -CN,
-NH
2 11. -NH-C(O)-CH 3 12. -NH-S0 2
-CH
3 13.
-N-(CH
3 2 14. -S0 2
-NH
2
-OH,
16.
17.
18.
19.
R2is 1.
2.
3.
4.
6.
7.
8.
9.
11.
12.
13.
14.
16.
17.
18.
19.
-O-CH2-(CHF 2
-S-CH
3
-S(O)-CH
3 -S(0) 2
-CH
3 or bromine, hydrogen atom, chlorine, fluorine, methoxy, methyl, bromine,
-C(O)-OH,
-C(O)-O-CH
3
-CN,
-NH
2
-NH-C(O)-CH
3 -NH-S0 2
-CH
3 -N-(CH3)2, -S0 2
-NH
2
-OH,
-O-CH
2
-(CHF
2
-S-CH
3
-S(O)-CH
3 or -S(0) 2
-CH
3 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring, and the other radical R1 or R3 has the abovementioned meaning of 1. to The invention furthermore relates to the use of compounds of the formula I where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, or 6. methyl, R2 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. methoxy, or methyl, or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring.
The invention furthermore relates to compounds of the formula I, o o R. ,RI RI N (I) R2 R3 R3 and/or all the stereoisomeric forms of the compound of the formula I, and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. halogen, 3. -(C 1 -C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 4. -O-(C 1
-C
4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, in which R4 is hydrogen atom or -(C 1
-C
4 )-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. -C(O)-(Cl-C4)-alkyl or 4. -S0 2
-(C
1 -C4)-alkyl, 8.
9.
11.
R2is 1.
2.
3.
4.
6.
7.
-OH,
-S-(C
1 -C4)-alkyl, -S(O)-(Cl-C4)-alkyl, -S(0) 2 -R7, in which R7 is -(C1-C4)-alkyl, -OH or -NH 2 hydrogen atom, halogen, -O-(Ci-C4)-alkyl,
-(C
1 -C4)-alkyl, in which R4 is hydrogen atom or -(C 1
-C
4 )-alkyl,
-CN,
in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. -C(O)-(C1-C4)-alkyl or 4. -S02-(C 1 -C4)-alkyl, 8. -OH, 9. -S-(C 1
-C
4 )-alkyl, 10. 1 -C4)-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C 1 -C4)-alkyl, -OH or -NH 2 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 11.
with the exception of the case where a) the radicals R1, R2 and R3 are all simultaneously hydrogen atom, or b) all the radicals R1, R2 and R3 are, independently of each other, only hydrogen atom, halogen, nitro, -(C1-C4)-alkyl or -(C1-C 4 )-alkoxy.
The invention furthermore relates to compounds of the formula I where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, in which alkyl is substituted once, twice or three times by halogen, 3. -O-(C1-C 4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, 4. -OH, in which R4 is hydrogen atom or -(C1-C4)-alkyl, 6. -CN, 7. -N(R5)R6, in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1
-C
4 )-alkyl, 3. -C(O)-(C1-C4)-alkyl or 4. -S02-(Cl-C4)-alkyl, 8. -S-(C 1 -C4)-alkyl, 9. -S(O)-(Cl-C4)-alkyl, or -S(0) 2 -R7, in which R7 is -(C1-C4)-alkyl, -OH or -NH 2 in which R1, R2 and R3, are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. halogen, 3. -O-(C 1 -C4)-alkyl, 4. -(C 1 -C4)-alkyl, 5. in which R4 is hydrogen atom or -(C1-C4)-alkyl, 6. -CN, 7. -N(R5)R6, in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. -C(O)-(Cl-C4)-alkyl, or 4. -S0 2
-(C
1 -C4)-alkyl, 8. -OH, 9. -S-(C 1
-C
4 )-alkyl, -S(O)-(Cl-C4)-alkyl, or 11. -S(0) 2 -R7, in which R7 is -(C 1 -C4)-alkyl, -OH or -NH 2 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 is 1. hydrogen atom, 2. halogen, 3. -(C 1 -C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 4. -O-(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, in which R4 is hydrogen atom or 4 )-alkyl, 6. -CN, 7. -N(R5)R6, in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. -C(O)-(Cl-C4)-alkyl, or 4. -S0 2
-(C
1 -C4)-alkyl, 8. -OH, 9. -S-(C 1
-C
4 )-alkyl, 1 -C4)-alkyl, or 11. -S(0) 2 -R7, in which R7 is -(C 1 -C4)-alkyl, -OH or -NH 2 The invention furthermore relates to compounds of the formula I, where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, 6. methyl, 7. -C(O)-OH, 8. -C(O)-O-CH 3 9. -CN,
-NH
2 11. -NH-C(O)-CH 3 12. -NH-S0 2
-CH
3 13. -N-(CH 3 2 14. -S0 2
-NH
2
-OH,
16. -O-CH 2
-(CHF
2 17. -S-CH 3 18. -S(O)-CH 3 19. -S(0) 2
-CH
3 or bromine, in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. methoxy, 5. methyl, 6. bromine, 7. -C(O)-OH, 8. -C(O)-O-CH 3 9. -CN,
-NH
2 11. -NH-C(O)-CH 3 12. -NH-S0 2
-CH
3 13. -N-(CH 3 2 14. -S0 2
-NH
2
-OH,
16. -O-CH 2
-(CHF
2 17. -S-CH 3 18. -S(O)-CH 3 or 19. -S(0) 2
-CH
3 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring, and the other radical R1 or R3 has the abovementioned meaning of 1. to The invention furthermore relates to the compounds of the formula I, and/or all the stereoisomeric forms of the compound of the formula I, and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1
-C
4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, or 3. -O-(C 1 -C4)-alkyl, in which alkyl is substituted once, twice or three times by halogen, in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. halogen, 3. -O-(C 1
-C
4 )-alkyl, or 4. -(C 1
-C
4 )-alkyl, or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 is 1. hydrogen atom, 2. halogen, 3. -(C 1 -C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, or 4. -O-(C 1
-C
4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen.
The invention furthermore relates to compounds of the formula I where A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, or 2. trifluoromethyl, in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. methoxy or 5. methyl, or R1 and R2 or R2 and R3 form, together with the nitrogen atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring, and the other radical R1 or R3 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, or 6. methyl.
The term "halogen" is understood as meaning fluorine, chlorine, bromine or iodine.
The term "(C 1
-C
4 )-alkyl" is understood as meaning hydrocarbon radicals whose carbon chain is straight-chain or branched and contains 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, i-propyl, butyl or tertiary butyl.
The term R1 and R2 or R2 and R3 form, together with the carbon atoms to which the are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur" is understood as meaning radicals which can be derived from dioxolane, pyrrole, pyrrolidine, pyridine, piperidine, tetrahydropyridine, pyrazole, imidazole, pyrazoline, imidazoline, pyrazolidine, imidazolidine, pyridazine, pyrimidine, pyrazine, piperazine, pyran, furan, dihydrofuran, tetrahydrofuran, oxazole, isoxazole, 2isoxazoline, isoxazolidine, morpholine, oxothiolane, thiopyran, thiazole, isothiazole, 2-isothiazoline, isothiazolidine or thiomorpholine.
The compounds of the formula I can be prepared, for example, by reacting a compound of the formula II o
T
C-Y
II
0 a) with a compound of the formula III R1 R2- NH2 I R3 where R1, R2 and R3 have the meanings given in formula I and Y is halogen, hydroxy or C 1
-C
4 -alkoxy or, together with the carbonyl group, forms an active ester or a mixed anhydride, with a compound of the formula I being formed and the reaction products being converted, where appropriate, into their physiologically tolerated salts, or b) reacting a compound of the formula II with a compound of the formula III to give a compound of the formula IV.
R1 NY (IV)
NNA
H
.A
R2" R3 where R1, R2 and R3 have the meanings given in formula I and Y is halogen, hydroxy or C1-C4-alkoxy or, together with the carbonyl group, forms an active ester or a mixed anhydride, and purifying the compound of the formula IV, where appropriate, and then converting it, with a compound of the formula III, into a compound of the formula I.
In that which follows, the preparation of compounds according to formula I and the preparation of the starting substances which are required for this purpose, insofar as they are not commercially available, are described in more detail.
The compounds according to the invention are prepared in the simplest manner by mixing together the two components, i.e. the pyrimidine or pyridine derivative according to formula (II) and the amine according to formula (III) in equimolar quantities or in up to about a 5-fold excess of III and reacting them at temperatures of between -300C and 150°C, preferably at from 200C up to 100 0 C, until the reaction has come to an end. When the compound of the formula IV is being prepared, the amine according to (III) is admixed up to an equimolar quantity of the compound of the formula III and reacted as above. The completion of the reaction can be determined, for example, with the aid of thin layer chromatography or HPLC-MS. A variant of this process is that the reaction is carried out in a suitable solvent, such as diethyl ether, dimethoxyethane or tetrahydrofuran, chlorinated hydrocarbons such as methylene chloride, chloroform or tri- or tetrachloroethylene, benzene or toluene, or else polar solvents such as dimethylformamide, acetone or dimethyl sulfoxide. In this case, too, it is possible to use an excess of amine according to formula (111), which excess can amount to up to about 5-fold quantities. The reaction temperatures in this case are between room temperature and the boiling point of the solvent, with temperatures in the range from room temperature up to 1300C being particularly preferred.
The reaction can also take place by way of a mixed anhydride such as ethyl chloroformate or by way of an active ester such as paranitrophenyl ester (Y
CICH
2 -COO or N0 2
-C
6 H4-O). Corresponding methods are described in the literature.
Where appropriate, the reaction can also take place in the presence of bases.
Examples of suitable additional bases are carbonates or hydrogen carbonates such as sodium carbonate or potassium carbonate or sodium hydrogen carbonate or potassium hydrogen carbonate, or tertiary amines, such as triethylamine, tributylamine or ethyldiisopropylamine, or heterocyclic amines, such as N-alkylmorpholine, pyridine, quinoline or dialkylanilines.
Where appropriate, the products, in particular the compound of the formula IV, can be worked up, for example, by extraction or chromatography, for example through silica gel. The isolated product can be recrystallized and, where appropriate, converted into a physiologically tolerated salt using a suitable acid. Examples of suitable acids which come into consideration are: mineral acids, such as hydrochloric acid and hydrobromic acid and also sulfuric acid, phosphoric acid, nitric acid or perchloric acid, or organic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, maleic acid, fumaric acid, phenylacetic acid, benzoic acid, methanesulfonic acid, toluenesulfonic acid, oxalic acid, 4-aminobenzoic acid, acid or ascorbic acid.
Insofar as they are not commercially available, the starting compounds of the formula (III) can be readily synthesized Organikum, Organisch Chemisches Grundpraktikum [Organikum, Basic Practical Course in Organic Chemistry], edtn., VEB Deutscher Verlag der Wissenschaften [VEB German Publishing Company for the Sciences], 1976; an overview of the various options can be found in the methods index, p. 822).
The starting compounds of the formula (II) can be obtained, for example, by converting pyrimidine-4,6-dicarboxylic acid or pyridine-2,4-dicarboxylic acid, respectively, into the corresponding pyrimidine-4,6-dicarbonyl halide, or, respectively, pyridine-2,4-dicarbonyl halide, preferably chloride (using methods known from the literature), preferably in the presence of a catalyst such as dimethylformamide. This acid halide can then be reacted, for example, either with a suitable alcohol, e.g. paranitrobenzyl alcohol, to give the corresponding active ester or else with lower alcohols, such as methanol or ethanol, to give the corresponding esters. The pyrimidine-4,6-dicarboxylic acid can also initially be converted, in the added presence of a suitable carboxylic acid or of a carboxylic ester, such as ethyl chloroformate, into a mixed anhydride, which is then reacted with the amines of the compound of the formulae (III) and (IV) to give the products according to the invention. An appropriate method is also described in the literature.
The pyrimidine-4,6-dicarboxylic acid is prepared using methods known from the literature, for example by oxidizing 4,6-dimethylpyrimidine, which, for its part, can be obtained, for example, by catalytically hydrogenating commercially obtainable 2-mercapto-4,6-dimethylpyrimidine.
Insofar as compounds of the formula I permit diastereoisomeric or enantiomeric forms, and accrue as their mixtures in connection with the chosen synthesis, the separation into the pure stereoisomers is achieved either by chromatography on an optionally chiral support material or, insofar as the racemic compound of the formula I is capable of sulfonation, by fractional crystallization of the diastereomeric salts which are formed using an optically active base or acid as auxiliary substance.
Examples of suitable chiral stationary phases for the thin-layer-chromatographic or column-chromatographic separation of enantiomers are modified silica gel supports (what are termed Pirkle phases) and also high molecular weight carbohydrates such as triacetylcellulose. Gas-chromatographic methods on chiral stationary phases can also be used for analytical purposes following appropriate derivatization, as known to the skilled person. In order to separate the racemic carboxylic acids into their enantiomers, the differently soluble diastereomeric salts are formed using an optically active base which can as a rule be obtained commercially, such as nicotine, and (-)-phenylethylamine, quinine bases, L-lysine or L- and D-arginine, the more difficulty soluble component is then isolated as a solid, the more readily soluble diastereomer is separated off from the mother liquor, and the pure enantiomers are then isolated from the diastereomeric salts which had been obtained in this way. The racemic compounds of the formula I which contain a basic group such as an amino group can in principle be converted into the pure enantiomers in the same way using optically active acids, such as sulfonic acid, D- and L-tartaric acid, D- and L-lactic acid and also and mandelic acid. Chiral compounds which contain alcohol or amine functions can also be converted into the corresponding esters or amides using appropriately activated or optionally N-protected enantiomerically pure amino acids or, conversely, chiral carboxylic acids can be converted into the amides using carboxy-protected enantiomerically pure amino acids or into the corresponding chiral esters using enantiomerically pure hydroxycarboxylic acids such as lactic acid. The chirality of the amino acid radical or alcohol radical which has been introduced in enantiomerically pure form can then be used for separating the isomers by means of separating the diastereomers, which are now present, by crystallization or chromatography on suitable stationary phases and, after that, once again eliminating the entrained chiral molecular moiety using suitable methods.
Acidic or basic products of the compound of the formula I can be present in the form of their salts or in free form. Preference is given to pharmacologically tolerated salts, for example alkali metal salts or alkaline earth metal salts or hydrochlorides, hydrobromides, sulfates, hemisulfates, all the possible phosphates, and also salts of the amino acids, natural bases or carboxylic acids.
Physiologically tolerated salts are prepared in a manner known per se from compounds of the formula I, including their stereoisomeric forms, which are capable of salt formation. The carboxylic acids and hydroxamine acids form stable alkali metal salts, alkaline earth metal salts or, where appropriate, substituted ammonium salts with basic reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethylamine or triethylamine, ethanolamine or triethanolamine, or else basic amino acids, for example lysine, ornithine or arginine. Insofar as the compounds of the formula I possess basic groups, stable acid addition salts can also be prepared using strong acids. Both inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, ptoluenesulfonic acid, 4-bromobenzenesulfonic acid, cyclohexylamidosulfonic acid, trifluoromethylsulfonic acid, acetic acid, oxalic acid, tartaric acid, succinic acid or trifluoroacetic acid, are suitable for this purpose.
Because of their pharmacological properties, the compounds of the formula I are suitable for the prophylaxis and therapy of all those diseases whose course involves an increased activity of matrix metalloproteinase 13.
These diseases include degenerative joint diseases such as osteoarthroses, spondyloses, chondrolysis following joint trauma or a relatively long period of joint immobilization following injuries to the meniscus or patella or the tearing of a ligament. In addition, they also include diseases of the connective tissue such as collagenoses, periodontal diseases, wound healing disturbances and chronic diseases of the locomotor system, such as inflammatory, immunologically or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism or forms of cancer such as breast cancer.
The pharmaceuticals according to the invention can be administered by subcutaneous, intraarticular, intraperitoneal or intravenous injection. Intraarticular injection is preferred. It is also possible to administer them rectally, orally, by inhalation or transdermally.
The invention also relates to a process for producing a pharmaceutical, in which process at least one compound of the formula I is brought, together with a pharmaceutically suitable and physiologically tolerated excipient and, where appropriate, further suitable active compounds, additives or auxiliary substances, into a suitable form for administration.
The compounds of the formula I are mixed with the additives which are suitable for this purpose, such as carrier substances, stabilizers or inert diluents and brought, using the customary methods, into suitable administration forms, such as tablets, sugar-coated tablets, hard gelatin capsules, aqueous alcoholic or oily suspensions or aqueous or oily solutions. Examples of inert carrier substances which can be used are gum arabic, magnesium oxide, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular corn starch. In this connection, the preparation can also be effected as dry granules or wet granules. Examples of suitable oily carrier substances or solvents are vegetable or animal oils, such as sunflower oil or cod liver oil.
For the purpose of subcutaneous, intraarticular, intraperitoneal or intravenous administration, the active compounds are, if desired, brought into solution, suspension or emulsion using the substances which are suitable for this purpose, such as solubilizers, emulsifiers or other auxiliary substances. Examples of suitable solvents are physiological sodium chloride solution or alcohols, for example ethanol, propanol or glycerol, and, in addition, sugar solutions, such as glucose or mannitol solutions, or else a mixture of the different solvents which have been mentioned.
In addition, use is made of customary adjuvants, such as carrier substances, disintegrants, binders, coating agents, swelling agents, glidants, lubricants, flavorants, sweeteners and solubilizers. Frequently employed auxiliary substances which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils, such as cod liver oil, sunflower oil, peanut oil or sesame oil, polyethylene glycol and solvents such as sterile water and monohydric or polyhydric alcohols, such as glycerol.
The compounds of formula I are preferably produced and administered as pharmaceutical preparations in dosage units, with each unit containing, as the active constituent, a particular dose of the compound of the formula I. For this purpose, they can be administered orally in doses of from 0.01 mg/kg/day to 25.0 mg/kg/day, preferably of from 0.01 mg/kg/day to 5.0 mg/kg/day, or parenterally in doses of from 0.001 mg/kg/day to 5 mg/kg/day, preferably of from 0.001 mg/kg/day to mg/kg/day. The dose can also be increased in severe cases. However, relatively small doses suffice in many cases. These figures relate to an adult weighing about 75 kg.
The invention is explained below with the aid of examples.
Examplel: Pyrimidine-4,6-dicarboxylic acid dibenzylamide (Formula I: R1 R2 H) 1.7 g of pyrimidine-4,6-dicarboxylic acid are suspended in 20 ml of toluene and 2.4 g of thionyl chloride and 0.2 ml of dimethylformamide are added. The mixture is heated to reflux until it is no longer possible to observe any gas evolution (about 3 hours About 5 ml of solvent are distilled off and the mixture is then cooled down to from 0°C to 10°C and 2.7 g of benzylamine, dissolved in 10 ml of toluene, are added.
The solution is slowly heated to room temperature, then stirred at room temperature for 12 hours and evaporated down to dryness. The residue is taken up in 50 ml of methylene chloride and the solution is extracted 3 times by shaking with saturated sodium hydrogen carbonate solution; the organic phase is washed with water, dried with magnesium sulfate and evaporated.
The solid is recrystallized from diisopropyl ether.
Yield: 2.1 g; 131°C to 1320C.
Example 2: Pyrimidine-4,6-dicarboxylic acid bis(3-chloro-4-fluorobenzylamide) (Formula I: R1 Cl; R2 F) N N SOC 2 N- N HO OH CI CI 0 0 0 0 O O O O CI
NH
2 F F
F
H N H
CH
2
CI
2 NEt 3 CI N N 0 0 200 mg (1.2 mmol) of pyrimidine-4,6-dicarboxylic acid were suspended in 0.3 ml (4.1 mmol) of thionyl chloride. This mixture was heated at 85°C for 2 h while being stirred. After it had been cooled down to room temperature, 2 ml of absolute dichloromethane were added. The suspension was cooled down to OC and 0.33 ml (2.4 mmol) of triethylamine was added. 861 mg (5.4 mmol) of 3-chloro-4fluorobenzylamine were added while stirring vigorously. The mixture was then stirred for a further 15 minutes. It was then diluted with 10 ml of dichloromethane after which 10 ml of water were added. After 5 minutes, the mixture was transferred into a separating funnel and the phases were separated. The organic phase was extracted twice with saturated sodium chloride solution and then dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure and the residue which was obtained in this way was dissolved in ethyl acetate. The product was crystallized from the solution by adding heptane. Beige-colored flakes were obtained and were dried under reduced pressure. Yield: 263 mg (49%) The following compounds were prepared in analogy with example 2.
Table 1: Example Structure MS (ESI+) 3 ac N N C 415.13 0 0 4 346.27 o CH 0
H
3 c N N .CH 3 375.26 O O 6 515.21 F N N rN F F F 00 FF F *F 22 F N N ~F 382.21 O 0 0 OH N o 9H 3 ce 0 N N N1 N.ON CH 3 406.31 0 0 O OH F F 419.22 N 7 N N F l;"I F O 0 11 V 7 N 7483.24 F N N N. F F 0 0 F 12 414.15 N N 0CCI 13 F N""N F 560.18 F F N N N F (M+MeCN) F 0 0 F 14 57; N"'N5 383.17 FN 7 N
F
0 0 F 7 NF 383.15 o 0 16 F N' N F 419.02 N N N F F 17 CH 3
CH
3 407.23 N N
N,
0 0 18 N- 375.13 H' N3C CH 3 0 0 19 415.06 clo a a0~ N 7 N 7 435.22 0N 7 N "N 0 0 Example 24 Dimethyl pyrimidine-4,6-dicarboxylate g (0.059 mol) of pyrimidine-4,6-dicarboxylic acid were suspended in 1.4 I of methanol, after which 10.93 ml (0.356 mol) of concentrated hydrochloric acid were added and the mixture was stirred at reflux (65 0 C) for 3 hours The reaction mixture was concentrated under reduced pressure after which the residue was taken up once again in methanol; the mixture was filtered and the resulting solution was concentrated.
Yield 11.02 g MS m/e 197.20 2.55 g (0.01299 mol) of the resulting compound dimethyl pyrimidine-4,6dicarboxylate were dissolved in 100 ml of dimethylformamide (DMF), after which 1.42 ml (0.01299 mol) of benzylamine were added and the mixture was heated to 500C. After 4 h, the solution is concentrated under reduced pressure. The residue is chromatographed through a 500 ml silica gel column using heptane/ethyl acetate Fractions containing the compound methyl 6-benzylcarbamoylpyrimidine-4carboxylate were concentrated.
Yield: 1.268 g MS m/e 272.20 200 mg (0.737 mmol) of the resulting compound methyl 6-benzylcarbamoylpyrimidine-4-carboxylate were dissolved in 4 ml of DMF, after which 225.98 mg (1.29 mmol) of 3-trifluoromethylbenzylamine were added and the mixture was stirred at for 1 day. After that, the solution was concentrated under reduced pressure.
The residue was purified by means of preparative HPLC (water/acetonitrile gradient, Purospher RP18). Fractions containing pyrimidine-4,6-dicarboxylic acid 4-benzylamide-6-(3-trifluoromethylbenzylamide) were concentrated under reduced pressure and freeze-dried. Yield: 240 mg MS m/e 415.27 The following compounds were prepared in an analogous manner: 0 0
RIO
Table 2 Example R10 radical MS m/e 3-fluorobenzylamine 365.23 26 4-fluorobenzylamine 365.23 27 3,4-difluorobenzylamine 383.27 28 4-methoxybenzylamine 377.28 29 3-methylbenzylamine 361.28 3-chlorobenzylamine 381.23 The following examples were prepared in analogy with the examples 1 and Table 3: Example Structure MS m/e 31 HCsO SN N 470.22 ES+ O 0 1
39
F
7 NZ N N y N Ni0 0 0 H 409.28 ES+
F
"N NyX,,, N "a F 0o -C 0 417.11
ES+
41
N~NF
0 0 441.25 42 0 N' N N
N
0 0 423.26 o o421.295E+ F~
N~NF
H
3 C Br'N_ 0 0 477.15 ES+ FNN
IN
o H-Cl 0 399.20 ES+ 46 F N~~N
-F
C N
N
N N N.N
F
0 -l 435.14 ES+ 393.33 ES+ 457.20 ES+ 379.19 ES+ H-Cl H-Cl H-Cl
F F F F N" N 0 o o 479.18 ES+ 66 N N
-I
o o 397.21 ES+ 67 N. N F 0 0 F 383.27 ES+ Pharmacological examples Determining the enzymic activity of the catalytic domain of human collagenase-3 (MMP-13).
This protein is obtained as an inactive proenzyme from INVITEK, Berlin (catalog No.
100 803). Activation of the proenzyme: 2 parts by volume of proenzyme are incubated with 1 part by volume of APMA solution at 37°C for 1.5 hours. The APMA solution is prepared from a 10 mmol/l solution of p-aminophenylmercuric acetate in 0.1 mmol/l NaOH by diluting it with 3 parts by volume of Tris/HCI buffer, pH 7.5 (see below). The pH is adjusted to between 7.0 and 7.5 by adding 1 mmol/l HCI. After the enzyme has been activated, it is diluted with the Tris/HCI buffer down to a concentration of 1.67 gg/ml.
In order to measure the enzyme activity, 10 pl of enzyme solution are incubated for minutes with 10 pil of a buffered 3% solution of dimethyl sulfoxide (reaction In order to measure the enzyme inhibitor activity, 10 pl of enzyme solution are incubated with 10 pl of a buffered 3% solution of dimethyl sulfoxide which contains the enzyme inhibitor (reaction 2).
Both in reaction 1 and in reaction 2, the enzyme reaction is monitored by fluorescence spectroscopy (328 nm (extinction)/393 nm (emission)) after 10 p/ of a 3% aqueous solution of dimethyl sulfoxide containing 0.75 mmol of the substrate/I have been added.
The enzyme activity is presented as increase in extinction/minute.
The inhibitor effect is calculated as percentage inhibition in accordance with the following formula: inhibition 100 [(increase in extinction/minute in reaction 2) (increase in extinction/minute in reaction 1) x 100].
The IC50, i.e. the concentration of inhibitor which is required for a 50% inhibition of the enzyme activity, is determined graphically by plotting the percentage inhibitions at different inhibitor concentrations.
The buffer solution contains 0.05% Brij (Sigma, Deisenhofen, Germany) and also 0.1 mol of Tris/HCI/I, 0.1 mol of NaCI/I and 0.01 mol of CaCl 2 /1 The enzyme solution contains 1.67 pg of the enzyme domain/ml.
The substrate solution contains 0.75 mmol of the fluorogenic substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-3-(2'.4'-dinitrophenyl)-L-2,3-diaminopropionyl- Ala-Arg-NH 2 /I (Bachem, Heidelberg, Germany).
The following table 4 shows the results.
Table 4: Example IC50 MMP13 (nM) Example IC50 MMP13 (nM) Example IC50 MMP13 (nM) 1 400 10 300 19 57 2 23 11 300 20 14 3 5600 12 260 21 4 3400 13 210 22 9 2000 14 200 23 8 6 700 15 190 7 620 16 105 8 400 17 9 320 18 72 SComparative example The compound pyrimidine-4,6-dicarboxylic acid diethylamide was prepared as described in EP 0418797. A value of 90 000 nM was obtained when the value for the inhibition of human collagenase -3 (MMP-13) was determined as c described in the above example. This compound therefore has practically no 0 o inhibitory effect on MMP 13.
Determining the enzymic activity of the catalytic domains of human neutrophil collagenase (MMP-8) and human stromelysin (MMP-3).
The enzymes human neutrophil collagenase and human stromelysin were prepared as active catalytic domains as described in Weithmann et al Inflamm Res, 46 (1997), pages 246-252 carried out. The measurement of the activity of the enzymes, and the determination of the inhibitory effect of inhbitors on the activity of the enzymes, were also carried out as described in that publication.
The compounds according to the abovementioned examples 1 to 23 in each case exhibited IC50 values of more than 100 000 nM when determining human neutrophil collagenase and human stromelysin. These compounds therefore have practically no inhibitory effect on MMP 3 and MMP 8.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (15)
1. A compound of the formula I, o o 00 a stereoisomeric form of the compound of the formula I, a physiologically tolerated salt of the compound of the formula I, or a mixture of two or more Ssubstances selected from the group comprising the compound of the formula 1, the stereoisomeric form of the compound of the formula 1 or the physiologically tolerated salt of the compound of the formula 1 wherein A is a nitrogen atom, R1 and R3 are identical or different and are, independently of each other 1. hydrogen atom,
2. halogen,
3. -(C1-C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,
4. -O-(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, in which R4 is hydrogen atom or -(C 1 -C 4 )-alkyl,
6. -CN,
7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C 4 )-alkyl, 3. -C(O)-(C1-C 4 )-alkyl or 4. -S0 2 -(C 1 -C 4 )-alkyl,
8. -OH,
9. -S-(Ci-C 4 )-alkyl, 1 -C 4 )-alkyl,
11. -S(0) 2 -R7, in which R 7 is -(C 1 -C 4 )-alkyl, -OH or -NH 2 Cc, In oo Cc, iO mt (N 0 0 R2 is 1. hydrogen atom, 2. halogen, 3. -(C 1 -C 4 )-alkyl, 4. -O-(C1-C 4 )-alkyl, in which R4 is hydrogen atom or -(C 1 -C 4 alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C1-C 4 )-alkyl, 3. 1 -C4)-alkyl or 4. -S0 2 -(C 1 -C4)-alkyl, 8. -OH, 9. -S-(C 1 -C4)-alkyl, -S(O)-(C1-C4)-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C 1 -C 4 )-alkyl, -OH or -NH 2 R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 11., with the exception of the case where a) the radicals R1, R2 and R3 are all simultaneously hydrogen atom, or b) all the radicals from R1, R2 and R3 are, independently of each other, only hydrogen atom, halogen, nitro, -(C 1 -C 4 )-alkyl or -(C 1 -C 4 )-alkoxy. 2. A compound of the formula I as claimed in claim 1, wherein A is a nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(Cl-0 4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, or 3. -O-(0 1 -C 4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, N 5 4. -OH, in which R4 is hydrogen atom or -(Cl-0 4 )-alkyl, 6. -ON, 00 7. -N(R5)-R6, in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(Cl-04)-alkyl, 3. -C(O)-(Cl-0 4 )-alkyl or 4. -S0 2 -(Cl-C 4 )-alkyl, 8. -S-(Cl-C 4 )-alkyl, 9. 1 -0 4 )-alkyl, or -S(O) 2 -R7, in which R7 is -(Cl-C 4 )-alkyl, -OH or -NH 2 in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. halogen, 3. -O-(0 1 -C 4 )-alkyl, 4. -(Cl-C4)-alkyl, in which R4 is hydrogen atom or -(Cli-0 4 )-alkyl, 6. -ON, 7. in which R5 and R6 are identical or different and are, independently of each other, 1 hydrogen atom, 2. -(Cl-0 4 )-alkyl, 3. -C(O0)-(O 1 -C 4 )-alkyl, or 4. -S0 2 -(Cl-C 4 )-alkyl, 8. -OH, 9. -S-(0 1 -0 4 )-alkyl, -S(O)-(Cl-C4)-alkyl, or 11. -S(O) 2 -R7, in which R7 is -(Cl-C 4 )-alkyl, -OH or -NH 2 or. 0 R1 and R2 or R2 and R3 form, together with the carbon atoms to which c they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 is 1. hydrogen atom, 2. halogen, 0 o 3. -(C1-C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice r or three times by halogen 4. -O-(C 1 -C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen in which R4 is hydrogen atom or -(C 1 -C 4 )-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C1-C 4 )-alkyl, 3. 1 -C 4 )-alkyl, or 4. -SO2-(C 1 -C 4 )-alkyl, 8. -OH, 9. -S-(C 1 -C 4 )-alkyl, -S(O)-(Ci-C 4 )-alkyl, or 11. -S(0) 2 -R7, in which R7 is -(C 1 -C4)-alkyl, -OH or -NH 2 3. A compound of the formula I as claimed in claim 1 or 2, wherein A is a nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, 6. methyl, 7. -0(O)-OH, 8. -O(O)-O-0H 3 9. -ON, -NH 2 11. -NH-C(O)-CH 3
12. -NH-S0 2 -CH 3
13. -N-(0H 3 2 00 14. -S0 2 -NH 2 -OH,
16. -O-0H 2 -(OHF 2
17. -S-OH 3
18. -S(O)-OH 3
19. -S(O) 2 -0H 3 or bromine, in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. methoxy, 5. methyl, 6. bromine, 7. -0(O)-OH, 8. -C(O)-O-CH 3 9. -ON, 10. -NH 2 11. -NH-O(O)-0H 3 12. -NH-S0 2 -CH 3 13. -N-(0H 3 2 14. -S0 2 -NH 2 15. -OH, 16. -O-CH 2 -(CHF 2 17. -S-OH 3 18. -S(O)-OH 3 or 19. -S(0) 2 -CH 3 or l R1 and R2 or R2 and R3 form, together with the carbon atoms to which i they are in each case bonded, a dioxolane, dihydrofuran or furan ring, and the other radical R1 or R3 has the abovementioned meaning of 1. to 4. A compound of the formula I as claimed in one or more of claims 1 to 3, a Sstereoisomeric form of the compound of the formula I, a physiologically 00 tolerated salt of the compound of the formula I, or a mixture of two or more Ssubstances selected from the group comprising the compound of the 0formula 1, the stereoisomeric form of the compound of the formula 1 or the N 10 physiologically tolerated salt of the compound of the formula 1 wherein A is a nitrogen atom R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C 4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, or 3. -O-(C 1 -C 4 )-alkyl, in which alkyl is substituted once, twice or three times by halogen, in which R1, R2 and R3 are not simultaneously hydrogen atom, and R2 is 1. hydrogen atom, 2. halogen, 3. -O-(C1-C4)-alkyl, or 4. -(C 1 -C 4 )-alkyl, or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 is 1. hydrogen atom, 2. halogen, 3. -(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, or 0 4. -O-(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, C twice or three times by halogen. A compound of the formula I as claimed in one or more of claims 1 to 4, C wherein A is a nitrogen atom, c R1 and R3 are identical or different and are, independently of each other, oO 1. hydrogen atom, or m 2. trifluoromethyl, O in which R1, R2 and R3 are not simultaneously hydrogen atom, and c 10 R2 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. methoxy or methyl, or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring and the other radical R1 or R3 is 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, or 4. methyl. 6. A process for preparing the compound of the formula I as claimed in one or more of claims 1 to 5, which comprises reacting a compound of the formula II N (II) II 0 O a) with a compound of the formula III R1 R2 NH 2 III R3 where R1, R2 and R3 have the meanings given in formula I as claimed in ¢q claim 1 and Y is halogen, hydroxyl or C 1 -C 4 -alkoxy or, together with the 00 oO carbonyl group, forms an active ester or a mixed anhydride, with a q compound of the formula I being formed and optionally, converting the reaction products into their physiologically tolerated salts, or b) reacting a compound of the formula II with a compound of the formula III to give a compound of the formula IV 0 o RI N~ R1 Y (IV) N, R2'* R3 where R1, R2 and R3 have the meanings given in formula I as claimed in claim 1 and Y is halogen, hydroxy or C 1 -C 4 -alkoxy or, together with the carbonyl group, forms an active ester or a mixed anhydride, optionally purifying the compound of the formula IV obtained, and then reacting the compound of formula IV with a compound of the formula III, to produce a compound of the formula I. 7. A pharmaceutical which comprises an effective amount of at least one compound of the formula I as claimed in one or more of claims 1 to together with a substance or compound selected from the group comprising a pharmaceutically suitable and physiologically tolerated carrier substance, additive or other active compound or auxiliary substance, or a combination thereof. 8. The use of the compound of the formula I N I 2 A R2 R2 IR3 N R3 Sa stereoisomeric form of the compound of the formula I, a physiologically r c tolerated salt of the compound of the formula I, or a mixture of two or more 00 substances selected from the group comprising the compound of the C~ 5 formula I, the stereoisomeric form of the compound of the formula I or the 0 physiologically tolerated salt of the compound of the formula I, for Sproducing a pharmaceutical for the prophylaxis and therapy of a disease selected from the group comprising osteoarthroses, spondyloses, chondrolysis following joint trauma or a relatively long period of joint immobilization following injuries to the meniscus or patella or tearing of a ligament, diseases of the connective tissue such as collagenoses, periodontal diseases and wound healing disturbances, chronic diseases of the locomotor system, such as inflammatory, immunologically or metabolism-determined acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism or breast cancer, wherein A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. halogen, 3. -(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 4. -O-(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, 5. in which R4 is hydrogen atom or -(C 1 -C 4 )-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C 4 )-alkyl, 3. 1 -C 4 )-alkyl or 0 4. -SO2-(C1-C 4 )-alkyl, 8. -OH, 9. -S-(C1-C 4 )-alkyl, 1 -C 4 )-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C1-C 4 )-alkyl, -OH or -NH 2 R2 is 1. hydrogen atom, 2. halogen, 3. (C-C4)-alkyl, 4 3. -O(C-C 4 )-alkyl, ¢q 4. -(C 1 -C 4 )-alkyl, 5. in which R4 is hydrogen atom or-(C 1 -C 4 )-alkyl, 6. -CN, 7. in which R5 and R6 are identical or different and are, independently of each other, 1. hydrogen atom, 2. -(C 1 -C4)-alkyl, 3. 1 -C 4 )-alkyl or 4. -S0 2 -(C 1 -C4)-alkyl, 8. -OH, 9. -S-(Cl-C 4 )-alkyl, 10. -S(O)-(Cl-C 4 )-alkyl, 11. -S(0) 2 -R7, in which R7 is -(C 1 -C 4 )-alkyl, -OH or -NH 2 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 11. 9. The use as claimed in claim 8, which comprises employing a compound of the formula I wherein A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, O 2. halogen, C 3. -(Cl-C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice Sor three times by halogen, 4. -O-(C 1 -C 4 )-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, R2 is 1. hydrogen atom, c 2. halogen, oo 3. -O-(C 1 -C 4 )-alkyl, or 4. -(C1-C 4 )-alkyl, or R1 and R2 or R2 and R3 form, together with the carbon atoms to which c they are in each case bonded, a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms from the series oxygen, nitrogen or sulfur, and the other radical R1 or R3 has the abovementioned meaning of 1. to 4. 10. The use as claimed in claims 8 and 9, which comprises employing a compound for the formula I wherein A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, 1. hydrogen atom, 2. chlorine, 3. fluorine, 4. trifluoromethyl, methoxy, 6. methyl, 7. -C(O)-OH, 8. -C(O)-O-CH 3 9. -CN, -NH 2 11. -NH-C(O)-CH 3 12. -NH-S0 2 -CH 3 13. -N-(CH 3 2 14. -S0 2 -NH 2 I O 15. -OH, c- 16. -O-CH 2 -(CHF 2 17. -S-CH 3 18. -S(O)-CH 3 19. -S(0) 2 -CH 3 or bromine, R2 is 1. hydrogen atom, 0 o 2. chlorine, r 3. fluorine, 4. methoxy, methyl, 6. bromine, 7. -C(O)-OH, 8. -C(O)-O-CH 3 9. -CN, -NH 2 11. -NH-C(O)-CH 3 12. -NH-S0 2 -CH 3 13. -N-(CH 3 2 14. -S0 2 -NH 2 -OH, 16. -O-CH 2 -(CHF 2 17. -S-CH 3 18. -S(O)-CH 3 or 19. -S(0) 2 -CH 3 or R1 and R2 or R2 and R3 form, together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring, and the other radical R1 or R3 has the abovementioned meaning of 1. to 11. The use as claimed in one or more of claims 8 to 10 which comprises employing a compound of the formula I wherein A is a carbon atom or nitrogen atom, R1 and R3 are identical or different and are, independently of each other, O 1. hydrogen atom, c 2. chlorine, 3. fluorine, 4. trifluoromethyl, N 5 5. methoxy, or 6. methyl, c R2 is 1. hydrogen atom, 00 2. chlorine, c 3. fluorine, 4. methoxy, or methyl, or R1 and R2 or R2 and R3 form together with the carbon atoms to which they are in each case bonded, a dioxolane, dihydrofuran or furan ring. SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT TRADE MARK ATTORNEYS P24085AU00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10160357.6 | 2001-08-12 | ||
DE10160357A DE10160357A1 (en) | 2001-12-08 | 2001-12-08 | Use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides for the selective inhibition of collagenases |
PCT/EP2002/013240 WO2003049738A1 (en) | 2001-12-08 | 2002-11-25 | Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002358535A1 AU2002358535A1 (en) | 2003-06-23 |
AU2002358535B2 true AU2002358535B2 (en) | 2007-05-10 |
Family
ID=7708512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002358535A Ceased AU2002358535B2 (en) | 2001-12-08 | 2002-11-25 | Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1455790B1 (en) |
JP (1) | JP4527980B2 (en) |
AT (1) | ATE390137T1 (en) |
AU (1) | AU2002358535B2 (en) |
CA (1) | CA2469625C (en) |
DE (2) | DE10160357A1 (en) |
IL (2) | IL162314A0 (en) |
MX (1) | MXPA04005129A (en) |
WO (1) | WO2003049738A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000328A (en) | 2001-02-14 | 2003-08-30 | Warner Lambert Co | MATRIX METALOPROTEINASH INHIBITING PYRIMIDINS |
DOP2002000332A (en) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | MATRIX METALOPROTEINAS PYRIDINE INHIBITORS |
DOP2002000333A (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | DERIVATIVES OF ISOFTALIC ACID AS INHIBITORS OF METALOPROTEINASES OF THE MATRIX |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
JP4164028B2 (en) | 2001-10-12 | 2008-10-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Alkyne matrix metalloproteinase inhibitors |
KR101050680B1 (en) * | 2002-11-02 | 2011-07-21 | 사노피-아벤티스 도이칠란트 게엠베하 | Novel pyrimidine-4,6-dicarboxamides for selective inhibition of collagenase |
DE10300017A1 (en) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selective MMP 13 inhibitors |
US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
KR20080087070A (en) * | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2008002671A2 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
WO2009140101A2 (en) * | 2008-05-12 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Imidazopyridine compounds useful as mmp-13 inhibitors |
GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0418797A2 (en) * | 1989-09-21 | 1991-03-27 | Hoechst Aktiengesellschaft | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds |
EP0463592A1 (en) * | 1990-06-28 | 1992-01-02 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and for their utilization |
WO2002064568A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyridine matrix metalloproteinase inhibitors |
WO2002064571A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000333A (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | DERIVATIVES OF ISOFTALIC ACID AS INHIBITORS OF METALOPROTEINASES OF THE MATRIX |
-
2001
- 2001-12-08 DE DE10160357A patent/DE10160357A1/en not_active Withdrawn
-
2002
- 2002-11-25 AU AU2002358535A patent/AU2002358535B2/en not_active Ceased
- 2002-11-25 WO PCT/EP2002/013240 patent/WO2003049738A1/en active IP Right Grant
- 2002-11-25 CA CA2469625A patent/CA2469625C/en not_active Expired - Fee Related
- 2002-11-25 MX MXPA04005129A patent/MXPA04005129A/en active IP Right Grant
- 2002-11-25 EP EP02792799A patent/EP1455790B1/en not_active Expired - Lifetime
- 2002-11-25 AT AT02792799T patent/ATE390137T1/en not_active IP Right Cessation
- 2002-11-25 IL IL16231402A patent/IL162314A0/en unknown
- 2002-11-25 JP JP2003550787A patent/JP4527980B2/en not_active Expired - Fee Related
- 2002-11-25 DE DE50211985T patent/DE50211985D1/en not_active Expired - Lifetime
-
2004
- 2004-06-02 IL IL162314A patent/IL162314A/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0418797A2 (en) * | 1989-09-21 | 1991-03-27 | Hoechst Aktiengesellschaft | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds |
EP0463592A1 (en) * | 1990-06-28 | 1992-01-02 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and for their utilization |
WO2002064568A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyridine matrix metalloproteinase inhibitors |
WO2002064571A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP2005513049A (en) | 2005-05-12 |
ATE390137T1 (en) | 2008-04-15 |
IL162314A (en) | 2011-07-31 |
CA2469625A1 (en) | 2003-06-19 |
DE50211985D1 (en) | 2008-05-08 |
CA2469625C (en) | 2011-07-26 |
DE10160357A1 (en) | 2003-06-18 |
EP1455790B1 (en) | 2008-03-26 |
WO2003049738A1 (en) | 2003-06-19 |
IL162314A0 (en) | 2005-11-20 |
AU2002358535A1 (en) | 2003-06-23 |
JP4527980B2 (en) | 2010-08-18 |
EP1455790A1 (en) | 2004-09-15 |
MXPA04005129A (en) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030229103A1 (en) | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases | |
AU2002358535B2 (en) | Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition | |
NO330345B1 (en) | Pyrimidine-4,6-dicarboxylic acid diamides, process for their preparation and composition containing at least one such compound | |
JP3247769B2 (en) | Novel piperazine and homopiperazine derivatives, pharmaceutical compositions containing these compounds and processes for producing these compounds | |
KR960011371B1 (en) | 2,4-and 2,5-pyridine-dicarboxylic-acid derivatives, process for their preparation, their use and medicines based on these compounds | |
CA2512183A1 (en) | Pyrimidine-4,6-dicarboxylic acid diamides for use as selective mmp 13 inhibitors | |
US20050004111A1 (en) | Selective MMP-13 inhibitors | |
US7166609B2 (en) | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | |
HU218274B (en) | N,n'-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them | |
DE10251019A1 (en) | New pyrimidine-4,6-dicarboxamide derivatives, are selective collagenase inhibitors useful e.g. for treating degenerative joint diseases, connective tissue disorders or cancer | |
FR2943675A1 (en) | ANTICANCER COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
MXPA06002927A (en) | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases. | |
CA2477474C (en) | Cyclic n-substituted alpha imino carboxylic acids for selective inhibition of collagenase | |
KR970011576B1 (en) | Benzimidazole derivatives having hetero aromatic amids | |
KR100243959B1 (en) | Mixed pyridine-2,4- and 2,5-dicarboxylic acid diamides, process for their preparation, their use as well as medicaments based on these compounds | |
HU208528B (en) | Process for producing pyridine-2,4- and 2.5-dicarboxylic acid-diamides and pharmaceutical compositions containing them | |
NZ539751A (en) | Pyrimidine-4,6-dicarboxylic acid diamides for the selectively inhibiting collagenase (MMP 13) | |
DE10254092A1 (en) | New pyrimidine-4,6-dicarboxamide derivatives, are selective collagenase inhibitors useful e.g. for treating degenerative joint diseases, connective tissue disorders or cancer | |
JPH0441143B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |